Minimal clinically important difference for asthma endpoints: An expert consensus report

European Respiratory Society 2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.

Anti-Asthmatic Agents; Asthma; Biomarkers; Bronchoconstriction; Consensus; Delphi Technique; Endpoint Determination; Humans; Inflammation Mediators; Lung; Predictive Value of Tests; Symptom Assessment; Treatment Outcome; Minimal Clinically Important Difference; Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO; info:eu-repo/semantics/article

Open access content. Open access content

English

SYC oai:publicatt.unicatt.it:10807/179991
10.1183/16000617.0137-2019
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85086063280
1256810840

UNIV CATTOLICA DEL SACRO CUORE
From OAIster®, provided by the OCLC Cooperative.

edsoai.on1256810840